Retatrutide
GLP-1/GIP/Glucagon Triple Agonist
Research Highlights
Triple receptor co-agonism — GLP-1, GIP, and Glucagon simultaneously
Studied for dose-dependent effects on body weight and adipose tissue reduction
Research models show superior metabolic efficacy vs dual GLP-1/GIP agonists
Influences hepatic glucose output, lipid metabolism, and energy expenditure
Lyophilized powder — reconstitution with bacteriostatic water or a suitable solvent is required prior to use. BAC Water is available separately in our Solvents category.
Retatrutide is a triple incretin receptor agonist (GIP/GLP-1/glucagon) under research for its metabolic effects, including body weight reduction1, improved glycaemic control2, and lipid profile modulation. Its tri-agonism model offers researchers a platform for studying how combined receptor activation influences energy homeostasis1.
Mechanism of Action
Simultaneous agonism at GIP, GLP-1, and glucagon receptors produces additive effects on insulin secretion, appetite suppression, hepatic glucose output, and energy expenditure.
Third-Party Verified
Certificates of Analysis
Every batch independently tested. COAs are published per lot.